BioCryst Pharmaceuticals Культура компании

Mr. Jon P. Stonehouse has been the Chief Executive Officer and Executive Director of BioCryst Pharmaceuticals, Inc. at Shionogi & Co., Ltd. since joining in January 8, 2007 and also has been its President since July 13, 2007. Mr. Stonehouse has over 20 years strong commercialization, Financial transaction, Business development and Management experience. Previously, he served as Senior Vice President of Corporate Development of Merck KGaA, since July 2002 and was responsible for global licensing and business development, corporate mergers and acquisitions, corporate strategic planning and alliance management. Among his accomplishments, he was responsible for leading the effort to develop a strategy for Merck that significantly changed Merck. Since March 2002, he served as Vice President of Global Licensing and Business Development and Integration of Merck KGaA, where he was responsible for the worldwide licensing and business development activities for the Ethical Pharmaceutical Division of Merck KGaA. Mr. Stonehouse joined EMD Pharmaceuticals, Inc. (the US Ethical Pharma division for Merck KGaA) in December 1999 as Vice President, Licensing and Business Development - Strategy & Integration and IT. Prior to Merck KGaA, he held a variety of roles at Astra erck/AstraZeneca including: Customer Unit Director, Director, Marketing & Sales - IT, National Sales Manager, National Sales Director - Managed Healthcare and Product Director - Omeprazole and was responsible for all clinical development and commercial activity for PRILOSEC in US. He started his career in the pharmaceutical industry as a Sales Representative, National Sales Trainer and District Sales Manager for Merck & Co., Inc. Mr. Stonehouse serves as a Member of Advisory Board of Genscript Biotech Corporation. He serves as a Member of Advisory board at Precision BioSciences, Inc. He has been a Director of Bellicum Pharmaceuticals, Inc. since December 2014. Mr. Stonehouse holds BS in Microbiology from the University of Minnesota.

Ms. Lynne M. Powell has been Chief Commercial Officer and Senior Vice President at BioCryst Pharmaceuticals, Inc. since January 26, 2015. Ms. Powell has 24 years of pharmaceutical industry experience. Ms. Powell served as Senior Vice President of North America Commercial Operations of CSL Behring LLC and was accountable for the financial performance and general management of CSL Behring's commercial activities within the U.S. and Canada. She joined CSL Limited in 1997 and has held key roles of increasing responsibility in Clinical Research, Project Management, Business Development, European Marketing and Global Commercial Development in Australia, Switzerland and the United States. Ms. Powell served as Vice President, Global Commercial Development at CSL Limited since 2004. In that role, she was responsible for global product commercialization and global strategic marketing. Ms. Powell launched five products globally for rare diseases, including hereditary angioedema (HAE). Prior to joining CSL, she held roles of increasing responsibility in GSK s predecessor companies, Glaxo/Glaxo Wellcome in the United Kingdom. She served in Clinical Research and Global Commercial Strategy. Ms. Powell holds a Bachelor of Science and Masters of Business Administration degrees.

Mr. Thomas R. Staab, also known as Tom, II, CPA, has been the Chief Financial Officer, Senior Vice President and Treasurer of BioCryst Pharmaceuticals, Inc. since July 1, 2011 and also has been its Principal Accounting Officer since January 25, 2013. Mr. Staab has nearly twenty years of finance and biotech accomplishments to BioCryst. His experience includes equity financing, strategic alliances, mergers and acquisitions, drug commercialization, SEC reporting, treasury management and investor relations. He served as Chief Financial Officer and Treasurer of Inspire Pharmaceuticals, Inc. since May 2003, Executive Vice President since September 1, 2008 and served as its Principal Accounting Officer. He served as Vice President of Inspire Pharmaceuticals, Inc., since May 2003. He joined Inspire Pharmaceuticals Inc., in May 2003. Previously, Mr. Staab held senior financial positions with Triangle Pharmaceuticals Inc. He served for five years at Triangle as its Vice President and Treasurer from August 2000 to May 2003 and its Acting Chief Financial Officer from July 2002 to May 2003. Prior to Triangle, he served at Price Waterhouse LLP for eight years, w here he worked with publicly and privately held companies focusing on audits, business advisory and tax services. He serves on the Board of the North Carolina Biosciences Organization. He also serves on the Board of the Triangle Community Foundation. He is a Certified Public Accountant. Mr. Staab received his BS in Business Administration and Master of Accounting degrees from The University of North Carolina, Chapel Hill.

Dr. Yarlagadda S. Babu, Ph.D., has been Senior Vice President of Drug Discovery at BioCryst Pharmaceuticals, Inc. since October 2013 and served as its Vice President of Drug Discovery since 1992. Dr. Babu joined BioCryst in 1988. He served five years on the biochemistry faculty at the University of Alabama at Birmingham. He obtained his Ph.D. from the Indian Institute of Science, Bangalore and spent three years in the Laboratory of Molecular Biophysics at the University of Oxford, UK before joining UAB.

Dr. William P. Sheridan, also known as Bill, MBBS, has been the Chief Medical Officer and Senior Vice President of BioCryst Pharmaceuticals, Inc. since July 1, 2008. Dr. Sheridan served as Vice President, Medical Affairs Europe of Amgen Inc. Previously, he served as the Vice President of North American Medical Affairs from March 2007 to November 2007. He served as Vice President of Global Development Group of Amgen since March 2000. He organized and led Amgen's US Medical Affairs function, making significant contributions to the successful launch of many compounds, including Aranesp ??? , Enbrel ??? , Kineret ??? , Neulasta ??? and Sensipar ???. Previously, at Amgen, he held titles at the Vice President level in International Medical Affairs, from March 2005 to February 2007; Global Health Economics, from January 2004 to January 2005; and Outcomes Research, US Medical Affairs and Product Development from January 2002 to December 2003. Prior to joining Amgen, he practiced medicine at the Royal Melbourne Hospital in Victoria, Australia as Head of the Bone Marrow Transplant Service. He spent 15 years in drug development at Amgen Pharmaceuticals, Inc. After leaving Amgen in November 2007 and prior to joining the Amgen, Dr. Sheridan served as an Independent Consultant for pharmaceutical companies, including BioCryst. He formed and led Amgen's US Medical Affairs group from 2002 to 2003 and served as Vice President of Global Health Economics since 2004. He led several product development teams, including Stem Cell Factor, Megakaryocyte Growth and Development Factor and Abarelix and subsequently led the Oncology and Inflammation therapeutic areas from March 1993 to 2001. He serves as Director of Kirin-Amgen and the Los Angeles Philharmonic Association and Dompe Biotec SpA. He served as Director of Bone Marrow Transplantation and a member of the hematology-oncology department at the Royal Melbourne Hospital, Melbourne, Australia and served as an investigator on Amgen clinical trials of filgrastim. He earned his MBBS degree (MD equivalent) at the University of Melbourne in Victoria. Dr. Sheridan is a board-certified fellow of the Royal Australasian College of Physicians (FRACP), with a sub-specialty in hematology and medical oncology.

Tom Staab serves as the CFO and Treasurer of BioCryst Pharmaceuticals, Inc.. Tom started at BioCryst Pharmaceuticals, Inc. in July of 2011. Tom currently resides in Raleigh-Durham, North Carolina Area.

William Sheridan serves as the Senior Vice President and Chief Medical Officer of BioCryst Pharmaceuticals, Inc.. William started at BioCryst Pharmaceuticals, Inc. in July of 2008. William currently resides in Raleigh-Durham, North Carolina Area.

Jinky Rosselli serves as the Vice President, Global Business Analysis & Operations of BioCryst Pharmaceuticals, Inc.. Jinky started at BioCryst Pharmaceuticals, Inc. in June of 2015. Jinky currently resides in Raleigh-Durham, North Carolina Area.